Obtained resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase domain mutations, specially the gatekeeper mutant T315I, is certainly a substantial problem for chronic myeloid leukemia (CML) patients. disease when portrayed in hematopoietic stem cells in mice (Daley et al., 1990). Motivated by Evofosfamide this, imatinib, a little molecule tyrosine kinase inhibitor (TKI) of… Continue reading Obtained resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase